Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
April 21 2020 - 5:18PM
Business Wire
Verastem, Inc. (NASDAQ: VSTM) (also known as Verastem Oncology),
a biopharmaceutical company committed to developing and
commercializing new medicines for patients battling cancer, today
announced that in light of public health and safety precautions
related to COVID-19, including restrictions on in-person
gatherings, the Company’s 2020 annual meeting of stockholders will
be changed from an in-person meeting to a virtual-only meeting. As
previously announced, the annual meeting will be held on May 19,
2020 at 9 a.m. Eastern Time, but stockholders will not be able to
attend in person. The virtual meeting will provide stockholders
with the ability to participate, vote their shares, and ask
questions.
As described in the proxy materials for the annual meeting
previously distributed, you are entitled to participate in the
annual meeting if you were a stockholder of record as of on March
23, 2020, the record date for the annual meeting.
To gain access to the meeting, you must go to the meeting
website at www.virtualshareholdermeeting.com/VSTM2020 (website will
be active prior to the meeting) and enter the 16-digit control
number provided on the proxy card, voting instruction form or
notice regarding the availability of proxy materials previously
received. The virtual meeting website will contain participation
instructions.
Whether or not planning to attend the annual meeting,
stockholders are encouraged to vote in advance of the annual
meeting by one of the methods described in the proxy materials.
Stockholders who have previously voted do not need to take any
further action. The proxy card and voting instruction form included
with the previously distributed proxy materials will not be updated
to reflect the change from an in-person meeting to a virtual-only
meeting and may continue to be used to vote shares in connection
with the annual meeting.
For further information, please refer to the Company’s proxy
statement and notice regarding the availability of proxy materials,
filed with the SEC on April 8, 2020, each of which can be accessed
at
https://investor.verastem.com/financial-information/sec-filings.
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial
biopharmaceutical company committed to the development and
commercialization of new medicines to improve the lives of patients
diagnosed with cancer. Our pipeline is focused on novel small
molecule drugs that inhibit critical signaling pathways in cancer
that promote cancer cell survival and tumor growth, including
phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK) and
RAF/MEK inhibition.
Our first FDA approved product is available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma
(iNHL).
For more information, please visit www.verastem.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200421005900/en/
Verastem Oncology: Investors: John Doyle Vice President,
Investor Relations & Finance +1 781-469-1546
jdoyle@verastem.com
Media: Lisa Buffington Corporate Communications +1 781-292-4205
lbuffington@verastem.com
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Verastem (NASDAQ:VSTM)
Historical Stock Chart
From Sep 2023 to Sep 2024